Janumet helps control blood-sugar levels by inhibiting an enzyme called DPP-4. It is linked to severe side effects such as bullous pemphigoid, pancreatic cancer or pancreatitis.
Do I Have a Janumet Lawsuit? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was injured, you should contact our lawyers immediately. You may be entitled to compensation by filing a lawsuit.
Janumet Side Effects
- Bile duct disease
- Bullous pemphigoid
- Gallbladder disease
- Heart failure
- Joint pain
- Pancreatic cancer
FDA Evaluating Rhabdomyolysis Risk
The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.
Janumet Linked to Severe Joint Pain
August 28, 2015 — The FDA has issued a Safety Communication about the risk of severe, disabling joint pain from Janumet. Click here to read more.
What is Janumet?
Janumet (sitagliptin / metformin) is a medication that is used in combination with diet and exercise to help control blood sugar in people with type-2 diabetes. It was developed by the drug company Merck and was approved by the U.S. Food and Drug Administration (FDA) in April 2007.
Merck developed sitagliptin, a major ingredient in Janumet. Sitagliptin inhibits the enzyme DPP-4, which causes the pancreas to produce extra insulin. Sitagliptin is the first FDA-approved medication that uses DPP-4 inhibition to treat diabetes.
Janumet uses several mechanisms to help a person with type-2 diabetes control their blood sugar. Janumet is actually a combination of two drugs:
- Sitagliptin: Sold alone under the brand-name Januvia, sitagliptin causes the pancreas to produce extra insulin, which lowers blood sugar. Side effects of sitagliptin include acute pancreatitis, hemorrhagic pancreatitis, necrotizing pancreatitis, pancreatic cancer, and more.
- Metformin: This medication prevents the body from absorbing as much sugar from food. It also limits the amount of glucose that the liver can produce, which can increase cellular insulin sensitivity. Side effects of metformin include cardiovascular events (heart attacks), lactic acidosis, and more.
Janumet and Cancer
Janumet contains sitagliptin, which inhibits the enzyme DPP-4 in the pancreas. Previous research has already determined that one function of DPP-4 is that it prevents cancerous tumors from spreading into nearby tissues.
In June 2011, the journal Gastroenterology published a study that found that people taking sitagliptin were 2.7-times more likely to develop pancreatic cancer. The researchers also found that people taking Byetta (a drug that is very similar to sitagliptin) were more likely to develop thyroid cancer.
Until more research can be conducted, this is an early warning sign. Janumet has not been available for very long, so there is not much long-term safety data. However, people taking Janumet may have a reduced ability to stop the progression of certain cancers, especially pancreatic cancer.
FDA Warnings for Janumet
The U.S. Food and Drug Administration (FDA) published this Drug Safety Warning in September 2009, after receiving 88 reports of acute pancreatitis between October 2006 and February 2009. The reports included 2 cases of hemorrhagic and necrotizing pancreatitis, which are the most life-threatening types of pancreatitis.
Do I have a Janumet Lawsuit?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact us for a free case review.